Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial

• Published in: BMC pediatrics Vol. 21; no. 1; p. 117
• Main Authors: Leach, Amanda Jane, Mulholland, Edward Kim, Santosham, Mathuram, Torzillo, Paul John, McIntyre, Peter, Smith-Vaughan, Heidi, Wilson, Nicole, Arrowsmith, Beth, Beissbarth, Jemima, Chatfield, Mark D, Oguoma, Victor M, Morris, Peter Stanley
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 08.03.2021; BioMed Central; BMC
• Subjects: Aboriginal; Age; Australia; Babies; Child; Combination schedule; Demographic aspects; Ear diseases; Ears & hearing; Families & family life; Haemophilus influenzae; Hearing loss; Humans; Immunization; Infant; Native peoples; Otitis media; Otitis Media - prevention & control; PCV13; Pediatric research; Pediatrics; Pneumococcal conjugate vaccines; Pneumococcal Infections - prevention & control; Pneumococcal vaccine; Pneumococcal Vaccines; Prevention; Proteins; Risk factors; Schedules; Statistics; Vaccines; Vaccines, Conjugate; Australia; Oceania; PCV13; Combination schedule; PHiD-CV10; Aboriginal; Head-to-head; Infant; Otitis media; Pneumococcal conjugate vaccines; 3-arm randomised controlled trial
• ISSN: 1471-2431; 1471-2431
• DOI: 10.1186/s12887-021-02552-z

Aboriginal children living in Australian remote communities are at high risk of early and persistent otitis media, hearing loss, and social disadvantage. Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) are the primary pathogens. We compared otitis media outcomes in infants randomised to either a combination of Synflorix™ (PHiD-CV10, with protein D of NTHi) and Prevenar13™ (PCV13, with 3, 6A, and 19A), with recommended schedules for each vaccine alone. We previously reported superior broader overall immunogenicity of the combination schedule at 7 months, and early superiority of PHiD-CV10 compared to PCV13 at 4 months. In an open-label superiority trial, we randomised (1:1:1) Aboriginal infants at 28 to 38 days of age, to either Prevenar13™ (P) at 2-4-6 months (_PPP), Synflorix™ (S) at 2-4-6 months (_SSS), or Synflorix™ at 1-2-4 months plus Prevenar13™ at 6 months (SSSP). Ears were assessed using tympanometry at 1 and 2 months, combined with otoscopy at 4, 6, and 7 months. A worst ear diagnosis was made for each child visit according to a severity hierarchy of normal, otitis media with effusion (OME), acute otitis media without perforation (AOMwoP), AOM with perforation (AOMwiP), and chronic suppurative otitis media (CSOM). Between September 2011 and September 2017, 425 infants were allocated to _PPP(143), _SSS(141) or SSSP(141). Ear assessments were successful in 96% scheduled visits. At 7 months prevalence of any OM was 91, 86, and 90% in the _PPP, _SSS, and SSSP groups, respectively. There were no significant differences in prevalence of any form of otitis media between vaccine groups at any age. Combined group prevalence of any OM was 43, 57, 82, 87, and 89% at 1, 2, 4, 6, and 7 months of age, respectively. Of 388 infants with ear assessments at 4, 6 and 7 months, 277 (71.4%) had OM that met criteria for specialist referral; rAOM, pOME, or CSOM. Despite superior broader overall immunogenicity of the combination schedule at 7 months, and early superiority of PHiD-CV10 compared to PCV13 at 4 months, there were no significant differences in prevalence of otitis media nor healthy ears throughout the first months of life. ACTRN12610000544077 registered 06/07/2010 and ClinicalTrials.gov NCT01174849 registered 04/08/2010.